The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 4, 2012, Pages 637-646

  Jiang, Chengying ^a,b   Hu, Fangke ^a,b   Tai, Yanhong ^a   Du, Jingli ^a   Mao, Beibei ^c   Yuan, Zengqiang ^c   Wang, Yan ^a   Wei, Lixin ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b NANKAI UNIVERSITY   (China)

^c INSTITUTE OF BIOPHYSICS   (China)

Author keywords

Hepatocellular carcinoma; Immunohistochemistry; PTPN11; Src homology phosphotyrosine phosphatase 2; Tissue microarray

Indexed keywords

PROTEIN TYROSINE PHOSPHATASE SHP 2;

ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ADULT; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MICROARRAY ANALYSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84863095061     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1143-5     Document Type: Article

References (16)

1. Bard-Chapeau EA, Li S, Ding J, Zhang SS, Zhu HH, Princen F, Fang DD, Han T, Bailly-Maitre B, Poli V, Varki NM, Wang H, Feng GS (2011) Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 19(5):629-639. doi:10. 1016/j.ccr.2011.03.023
2. Chan RJ, Feng GS (2007) PTPN11 is the first identified protooncogene that encodes a tyrosine phosphatase. Blood 109(3): 862-867. doi:10.1182/blood-2006- 07-028829 (Pubitemid 46220628)
3. Chan G, Kalaitzidis D, Neel BG (2008) The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev 27(2):179-192. doi: 10.1007/s10555-008-9126-y
4. Fleming I, Cooper J, Henson D (1997) AJCC cancer staging manual, 5th edn. Lippincott-Raven, Philadelphia, pp 98-126
5. Fridberg M, Kjellstrom S, Anagnostaki L, Skogvall I, Mustelin T, Wiebe T, Persson JL, Dictor M, Wingren AG (2008) Immunohistochemical analyses of phosphatases in childhood B-cell lymphoma: lower expression of PTEN and HePTP and higher number of positive cells for nuclear SHP2 in B-cell lymphoma cases compared to controls. Pediatr Hematol Oncol 25(6): 528-540. doi:10.1080/ 08880010802237054
6. Grinnell KL, Casserly B, Harrington EO (2010) Role of protein tyrosine phosphatase SHP2 in barrier function of pulmonary endothelium. Am J Physiol Lung Cell Mol Physiol 298(3):L361-L370. doi:10.1152/ajplung.00374.2009
7. Keilhack H, David FS, McGregor M, Cantley LC, Neel BG (2005) Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem 280(35):30984-30993. doi: 10.1074/jbc.M504699200 (Pubitemid 41291831)
8. Kim JS, Shin OR, Kim HK, Cho YS, An CH, Lim KW, Kim SS (2010) Overexpression of protein phosphatase non-receptor type 11 (PTPN11) in gastric carcinomas. Dig Dis Sci 55(6):1565-1569. doi:10.1007/s10620-009-0924-z
9. Li HY, Liu H, Wang CH, Zhang JY, Man JH, Gao YF, Zhang PJ, Li WH, Zhao J, Pan X, Zhou T, Gong WL, Li AL, Zhang XM (2008) Deactivation of the kinase IKK by CUEDC2 through recruitment of the phosphatase PP1. Nat Immunol 9(5):533-541. doi:10.1038/ni.1600 (Pubitemid 351560522)
10. Matozaki T, Murata Y, Saito Y, Okazawa H, Ohnishi H (2009) Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci 100(10):1786-1793. doi:10.1111/j.1349-7006.2009.01257.x
11. McClelland RA, Finlay P, Walker KJ, Nicholson D, Robertson JF, Blamey RW, Nicholson RI (1990) Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res 50(12):3545-3550 (Pubitemid 20194093)
12. Miyamoto D, Miyamoto M, Takahashi A, Yomogita Y, Higashi H, Kondo S, Hatakeyama M (2008) Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors. Oncogene 27(25):3508-3515. doi:10.1038/sj.onc.1211019 (Pubitemid 351793798)
13. Ostman A, Hellberg C, Bohmer FD (2006) Protein-tyrosine phosphatases and cancer. Nat Rev Cancer 6(4):307-320. doi:10.1038/ nrc1837
14. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT, Luk JM (2009) Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 115(19):4576-4585. doi:10.1002/cncr.24495
15. Yu SJ, Yu JK, Ge WT, Hu HG, Yuan Y, Zheng S (2011) SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer. World J Gastroenterol 17(15):2028-2036. doi:10.3748/wjg.v17.i15.2028
16. Zhou XD, Agazie YM (2008) Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells. Cell Death Differ 15(6):988-996. doi:10.1038/cdd.2008.54 (Pubitemid 351712603)